152803-05-9

Upstream product

• 1531598-56-7 5-(3-hydroxy-3-methylbut-1-yn-1-yl)nicotinonitrile 
• 35590-37-5 5-bromopyridine-3-carbonitrile 
• 866683-29-6 5-((trimethylsilyl)ethynyl)nicotinonitrile 

Downstream Products

• 1213234-98-0 5-[1-(3,4,5-tribromobenzyl)-1H-1,2,3-triazol-4-yl]nicotinonitrile 
• 1213235-00-7 ethyl (5-{5-[1-(3,4,5-tribromobenzyl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}-2H-tetrazol-2-yl)acetate 
• 1213234-99-1 C₁₅H₉Br₃N₈ 
• 1213234-73-1 (5-{5-[1-(3,4,5-Tribromobenzyl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}-2H-tetrazol-2-yl)acetic acid 
• 106726-82-3 3-Cyano-5-methoxycarbonylpyridine 
• 866685-17-8 5-(3-hydroxy-4-fluorophenylethynyl)-nicotinonitrile 
• 866683-66-1 5-(4-fluoro-3-hydroxymethylphenylethynyl)-nicotinonitrile 
• 866684-15-3 5-(3,4-dimethylphenylethynyl)-nicotinonitrile 
• 866684-05-1 5-(2-chlorophenylethynyl)-nicotinonitrile 

Relevant academic research and scientific papers

Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues

Fifty novel prodrugs and aza-analogues of 3,5-bis(4-amidinophenyl)isoxazole and its derivatives were prepared. Eighteen of the 24 aza-analogues exhibited IC50 values below 25 nM against Trypanosoma brucei rhodesiense or Plasmodium falciparum. S

HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and tr

Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors

It has been demonstrated that once-a-day dosing of systemically-distributed SCD inhibitors leads to adverse events in eye and skin. Herein, we describe our efforts to convert a novel class of systemically-distributed potent triazole-based uHTS hits into liver-targeted SCD inhibitors as a means to circumvent chronic toxicity.

PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS

The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C1-C4 alkyl, C1-C4 alkoxy, C1-C5 acyl, halo, amino, nitro, cyano, hydroxy, C1-C5 acylamino, C1-C4 alkylsulfonylamino, mono-, di- or trifluorinated C1-C3 alkyl, substituents which may be the same or different and may bear a CONH2, CONHCH3, CON(CH3)2, CO2H, CO2CH3, OCF3, CH2NHCOCH3, CH2NH2, CH2N(CH3)2, CH2CN, CH2OH, CH2NHSO2CH3, CH2N(CH3)(CH2)2 CN, CH2N(CH3)CH(CH3)2, CH2NHCH(CH3)2, CH2NH(CH2)2CH3, CH2NHCO2R4, CH2NHCH2CH3, CH2NHCH3 NHCOC(CH3)2, or N(S(O)2CH3)2 substituent; R1 is hydrogen, halo, R4, CN, C(NOH)R3, C(NO-R4)R3, (CH)2CO2R4 , (CH2)n OR3 , COR3 , CF3,SR4 , S(O)R4, S(O)2R4, COCH2CO2R3 , NHSO2R4 , NHCOR3, C(NOR3)NH2, CH2OCOR3,(CH2)n NH2, CON(CH3)2 (CH2)nNHCO2R4 , CO2R3, CONH2, CSNH2, C(NH)NHOR3, (CH2)nN(CH3)2, or CONHNHCOR3; R2 is 1,2-ethenediyl or 1,2-ethynediyl; R3 is hydrogen or C1-C4 alkyl; R4 is C1-C4 alkyl; and n is 0, 1, 2,3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.